Categories
Anticancer Drugs Medicine Oncology Pembrolizumab Pharmacology Physiotherapy

Pembrolizumab

In this article we will discuss about Pembrolizumab (Dosage)

In this article, we will discuss about Pembrolizumab (Dosage). So, let’s get started.

Dosage

Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks.

Non-Small Cell Lung Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Small Cell Lung Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Head and Neck Squamous Cell Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Classical Hodgkin Lymphoma or Primary Mediastinal Large B-Cell Lymphoma: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.

Urothelial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.

Microsatellite Instability-High or Microsatellite Instability-High or Mismatch Repair Deficient Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for
pediatrics.

Microsatellite Instability-High or Microsatellite Instability-High or Mismatch Repair Deficient Cancer Colorectal Cancer: 200 mg every 3 weeks or 400 mg every
6 weeks.

Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks.

Hepatocellular Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks.

Merkel Cell Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.

Renal Cell Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with axitinib 5 mg orally twice daily.

Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with lenvatinib 20 mg orally once daily for tumors that are not MSI-H or DMMR.

Tumor Mutational Burden-High Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics.

Cutaneous Squamous Cell Carcinoma: 200 mg every weeks or 400 mg every 6 weeks.

Triple Negative Breast Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. Administer Pembrolizumab (KEYTRUDA®) as an intravenous infusion over 30 minutes.

Adverse Reactions

Most common adverse reactions (reported in ≥20% of patients) were:

Pembrolizumab (KEYTRUDA®) as a single agent fatigue, musculoskeletal pain, decreased appetite, pruritus. diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain.

Pembrolizumab (KEYTRUDA®) in combination with chemotherapy: fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, and weight loss.

Pembrolizumab (KEYTRUDA®) in combination with axitinib: diarrhea,
fatigue, asthenia, hypertension, hepatotoxicity. hypothyroidism,
decreased appetite, palmar-plantar erythrodysesthesia, nausea,
stomatitis/mucosal inflammation, dysphonia, rash, cough, and
constipation.

Pembrolizumab (KEYTRUDA®) in combination with lenvatinib: fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, weight loss, abdominal pain, headache. constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar
erythrodysesthesia, dyspnea, cough, and rash.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.